JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M105673200 on July 23, 2001

J. Biol. Chem., Vol. 276, Issue 38, 35622-35628, September 21, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/38/35622    most recent
M105673200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Banno, Y.
Right arrow Articles by Nozawa, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Banno, Y.
Right arrow Articles by Nozawa, Y.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Involvement of Phospholipase D in Sphingosine 1-Phosphate-induced Activation of Phosphatidylinositol 3-Kinase and Akt in Chinese Hamster Ovary Cells Overexpressing EDG3*

Yoshiko BannoDagger §, Yoh Takuwa, Yukihiro Akao||, Hiroyuki Okamoto, Yosuke Osawa**, Takashi NaganawaDagger , Shigeru NakashimaDagger , Pann-Ghill SuhDagger Dagger , and Yoshinori Nozawa||

From the Departments of Dagger  Biochemistry and ** Internal Medicine, Gifu University School of Medicine, Gifu 500-8705, Japan,  Department of Physiology, Kanazawa University School of Medicine, Kanazawa 920-8640, Japan, || Gifu International Institute of Biotechnology and Institute of Applied Biochemistry, Mitake, Gifu 505-0116, Japan, and Dagger Dagger  Department of Life Science, Division of Molecular and Life Sciences, Pohang University of Science & Technology, Pohang 790-784, South Korea

Received for publication, June 20, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Phospholipase D (PLD), phosphatidylinositol 3-kinase (PI3K), and Akt are known to be involved in cellular signaling related to proliferation and cell survival. In this report, we provide evidence that PLD links sphingosine 1-phosphate (S1P)-induced activation of the G protein-coupled EDG3 receptor to stimulation of PI3K and its downstream effector Akt in Chinese hamster ovary (CHO) cells. S1P stimulation of EDG3-overexpressing CHO cells but not vector-transfected cells induced activation of PLD, PI3K, and Akt in a time- and dose-dependent manner. Akt phosphorylation was prevented by the PI3K inhibitors wortmannin and LY294002 (2-(4-monrpholinyl)-8-phenyl-4H-1-benzopyran-4-one), indicating that Akt activation was dependent on PI3K. S1P-induced activation of PI3K and Akt was abrogated by 1-butanol, which inhibited S1P-induced accumulation of phosphatidic acid by serving as a phosphatidyl group acceptor in the transphosphatidylation reaction catalyzed by PLD, whereas both PI3K and Akt activation were not inhibited by 2-butanol without such reaction. Co-expression of wild-type PLD2 with myc-Akt resulted in increased Akt activation in response to S1P. In contrast, co-expression of a catalytically inactive mutant of PLD2 eliminated the S1P-induced Akt activation. The treatment of EDG3-expressing CHO cells with exogenous Streptomyces chromofuscus PLD, which caused an accumulation of phosphatidic acid, resulted in increases in PI3K activity and the phosphorylation of Akt, the latter of which was completely abolished by LY294002. Furthermore, S1P-induced membrane ruffling, which was dependent on PI3K and Rac, was inhibited by 1-butanol, but not by 2-butanol. These results demonstrate that PLD participates in the activation of PI3K and Akt stimulation of EDG3 receptor.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Hydrolysis of phosphatidylcholine by phospholipase D (PLD)1 to generate phosphatidic acid (PA) and choline has been implicated in a variety of cellular responses, including rapid responses such as secretion and cytoskeletal reorganization as well as proliferation, differentiation, and apoptosis (1-3). Two mammalian PLDs, PLD1 and PLD2, have been identified that differ in terms of cellular localization and function (1-5). A number of reports have pointed to the ability of PA to modify, in cell-free systems, the activities of components playing key roles in signal transduction, including serine/threonine protein kinases (6-8), protein phosphatases (9, 10), GTPase-activating proteins (11), lipid kinases (12, 13), phospholipases (14, 15), and NADPH oxidase (16). However, it remains unclear whether PA exerts in vivo regulatory effects on these signaling molecules. A recent study has demonstrated that in insulin-stimulated cells, PA derived from PLD2 activation takes part in the Ras-mitogen-activated protein kinase signaling pathway by promoting recruitment to the membrane and activation of Raf-1 (17).

Sphingosine 1-phosphate (S1P), a metabolite of sphingomyelin, acts as a second messenger and also as a high-affinity agonist for the EDG family of G protein-coupled cell surface receptors, which includes EDG1, EDG3, EDG5, EDG6, and EDG8 (18-20). The cellular responses elicited by S1P include stimulation of mitogenesis, cell differentiation, smooth muscle contraction, regulation of cell migration, inhibition of tumor cell invasion (18-24), activation of several enzymes such as phospholipase C, adenylate cyclase, mitogen-activated protein kinase family protein kinases, phosphatidylinositol 3-kinase (PI3K), and PLD, and Cas tyrosine phosphorylation (25-31). A potential role for S1P in cell proliferation and survival has been suggested based on its ability to antagonize the apoptosis-inducing effects of ceramide (32) and to activate mitogen-activated protein kinase followed by activation of c-Fos, activations that are mediated via EDG3 and EDG5 (33). However, the mechanisms of S1P action underlying cell survival activity are not fully understood. Recent studies have demonstrated that PLD participates in cell proliferation and antiapoptosis (34-37), but little information is available regarding the involvement of PLD in signaling related to proliferation and survival. However, a wealth of evidence has demonstrated that PI3K does play an important role in this signaling. More specifically, the serine/threonine kinase Akt/protein kinase B has been found to be a critical downstream effector of PI3K in cell survival signaling (38). In addition, we have recently demonstrated that S1P induces PI3K activation via EDG1, EDG3, and EDG5. S1P induced membrane ruffling and cell migration in a PI3K- and Rac-dependent manner (39). Interestingly, PLD has also been shown to be involved in this membrane ruffling (40). Thus, it is of interest to determine whether PLD is involved in S1P-induced activation of the PI3K/Akt pathway and, if so, how.

In the present study, we demonstrate that inhibition of PA accumulation and expression of a catalytically inactive mutant of PLD2 strongly inhibit EDG3-mediated stimulation of PI3K and Akt, whereas exogenous PLD alone induces stimulation of PI3K and Akt. These observations indicate a novel role for PLD in the PI3K signaling pathway.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Geneticin (G418) and Streptomyces chromofuscus PLD were obtained from Sigma, S1P was obtained from Matreya, Inc. (Pleasant Gap, PA), [9,10-3H]palmitic acid (54.0 Ci/mmol) and [gamma -32P]ATP (3000 Ci/mmol) were obtained from PerkinElmer Life Sciences, and wortmannin and LY294002 were obtained from Calbiochem. Antibodies to phosphorylated Akt (Ser-473) and Akt were obtained from New England Biolabs (Boston, MA), and anti-phosphotyrosine (PY-20) antibody was obtained from Transduction Laboratories (Lexington, KY). Polyclonal anti-PLD1 and anti-PLD2 antibodies were prepared as described previously (25). Monoclonal anti-myc antibody (9E10)-producing hybridoma cells were obtained from American Type Culture Collection. Anti-rabbit and anti-mouse antibodies conjugated with horseradish peroxidase and chemiluminescence kit (ECL system) were obtained from Amersham Pharmacia Biotech. Expression plasmids of wild-type human PLD1 and mouse PLD2 and their catalytically inactive mutants (K898R and K758R, respectively) in pCGN were kindly supplied by Dr. Michael A. Frohman (Institute for Cell and Developmental Biology, State University of New York), and Myc- and 6×His-tagged Akt plasmids (pUSE-myc-Akt) were obtained from Upstate Biotechnology (Lake Placid, NY). All other reagents were obtained from standard commercial sources.

Cell Culture and Transfections-- CHO-K1 cells were cultured in Ham's F-12 medium supplemented with 10% (v/v) fetal bovine serum, 100 units/ml penicillin G, and 100 mg/ml streptomycin at 37 °C in a humidified, CO2-controlled (5%) incubator. Before each experiment, cells were switched to the serum-free Ham's F-12 medium. Human EDG3 cDNA was cloned and ligated into expression vector pME18S as described previously (41). The stable transfectants of pME18S empty vector and pME18S-EDG3 were selected and maintained in the presence of 0.75 mg/ml G418 as described previously (42). For transient transfection experiments, cells were plated at 8 × 105 cells/plate in 60-mm plates and cultured for 24 h before transfection. Cells were incubated for 4 h with 2 ml of serum-free Ham's F-12 medium containing 3 µg of total DNA (1 µg of pUSE-myc-Akt and 2 µg of expression plasmid for a pCGN-wild-type or an inactive mutant of PLDs, or an empty vector) and 15 µl of LipofectAMINE (Life Technologies, Inc.). The medium was changed to growth medium, and the cells were cultured for 24 h. The cells were serum-starved by further incubation in serum-free Ham's F-12 medium for 24 h.

Measurement of PLD Activity-- Subconfluent cells were labeled for 24 h with 1 mCi/ml [3H]palmitic acid in serum-free Ham's F-12 medium. Cells were washed and preincubated in HEPES-Tyrode buffer containing 0.3% 1-butanol (v/v) for 10 min. After stimulation of cells with S1P, the reactions were terminated by removing the assay buffer, followed by the immediate addition of 1 ml of an ice-cold phosphate-buffered saline/methanol (2:5, v/v) mixture to the culture dishes. After extraction of cellular lipids, [3H]PBut was separated by TLC and measured as described previously (25). [3H]PA was measured by the same method as described for the PBut formation, except that incubation was performed using HEPES-Tyrode buffer without 1-butanol.

Determination of Akt Phosphorylation-- Cells were grown to subconfluence in 100-mm dishes and incubated in serum-free Ham's F-12 medium for an additional 24 h. Washed cells were then stimulated with S1P, harvested in an ice-cold lysis buffer (1% Nonidet P-40, 0.5% sodium cholate, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 20 mM HEPES, 3 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, 20 µg/ml leupeptin, 20 mM beta -glycerophosphate, 1 mM sodium fluoride, and 1 mM sodium orthovanadate, pH 7.4), and then sonicated. Protein concentrations were assayed using the Bradford protein assay reagent (Bio-Rad) with bovine serum albumin as a standard. Total cell lysates (50 µg of protein) were subjected to electrophoresis on 10% SDS-polyacrylamide gel and transferred to polyvinylidene difluoride membranes (Millipore). The membranes were blocked with 5% bovine serum albumin. Phosphorylation of Akt and the total amount of Akt were determined by immunoblotting with rabbit polyclonal anti-phospho-Akt (Ser-473) and anti-Akt antibodies, respectively, and with horseradish peroxidase-linked secondary antibody. After repeated washings, the antibodies were detected using the ECL Western blotting detection system.

Immunocomplex Akt Kinase Assays-- Akt activity was assayed as described previously (43). Briefly, after treatment, cells were harvested in an ice-cold lysis buffer, and insoluble materials were removed by centrifugation at 14,000 × g for 15 min. The lysate was incubated with 9E10 antibody against myc for 1 h and then incubated with protein A-Sepharose conjugated with anti-mouse rabbit IgG for 2 h. The beads were washed with the lysis buffer and then washed twice with a kinase buffer (20 mM 4-morpholinepropanesulfonic acid, pH 7.2, 25 mM beta -glycerophosphate, 5 mM EGTA, 1 mM sodium orthovanadate, and 1 mM dithiothreitol), respectively. The beads were then resuspended in 20 µl of kinase buffer. The reaction was started by adding 10 µl of 0.4 mM Crosstide (Upstate Biotechnology) and 10 µl of ATP solution (0.5 mM ATP, 10 µCi of [gamma -32P]ATP, and 75 mM MgCl2), and the reaction mixture was then incubated at 30 °C for 10 min. Reactions were centrifuged for 2 min at 14,000 × g, and 40 µl of the supernatant was then removed and placed in another tube. After 20 µl of 40% trichloroacetic acid was added to the supernatant solution, the mixture was incubated for 5 min at room temperature. The supernatant solution (40 µl) was spotted onto 2-cm2 pieces of P81 filter paper (Whatman), followed by extensive washing in 1% (v/v) phosphoric acid and then in acetone. Measurement of the associated radioactivity of the filter paper was carried out by liquid scintillation counting.

Immunocomplex PI3K Assay-- After incubation with S1P, the cells were harvested in ice-cold lysis buffer. The lysate was incubated with 4 mg of PY-20 anti-phosphotyrosine antibody for 1 h and then incubated for 2 h with protein A-Sepharose conjugated with anti-mouse rabbit IgG as described by Ruderman et al. (44). Briefly, the immunoprecipitates were washed twice with a lysis buffer, once with 0.5 M LiCl/0.1 M Tris-HCl, pH 7.5, once with distilled water, and then once with washing buffer (20 mM Tris-HCl, pH 7.5, 100 mM NaCl, and 1 mM EDTA). The lipid kinase assay and lipid extraction were performed as described previously (45), except that micelles of PI were produced by sonication in an assay buffer (20 mM Tris-HCl, pH 7.5, 100 mM NaCl, and 0.5 mM EDTA). Phospholipids contained in the organic phase were separated by TLC in chloroform/methanol/water/ammonia (60:47:11:3.2, v/v). Spots containing [32P]PI3-phosphate (PI3P) were scraped off the plate and quantitated by liquid scintillation counting.

Fluorescence Microscopy-- Cells cultured in 35-mm-diameter dishes on glass coverslips were fixed in 3.7% formaldehyde, permeabilized in 0.25% Triton X-100, and blocked with 3% bovine serum albumin in phosphate-buffered saline (39). Alexa Fluor 546 phalloidin (Molecular Probes) was used to visualize F-actin. The cells were observed under a BX60 inverted fluorescence microscope (Olympus, Tokyo, Japan).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

S1P-induced Phospholipase D Activation in EDG3-Over-expressing CHO-K1 Cells-- We first examined whether EDG3 mediated S1P-induced PLD activation. S1P stimulation increased PBut formation dose-dependently with a half-maximal effective concentration value of ~10-7 M in EDG3-CHO-K1 cells (Fig. 1A) and time-dependently with a plateau attained at 5 min (Fig. 1B). However, no significant increase in PBut formation was observed in response to S1P in vector-transfected control CHO-K1 cells. These results are indicative of EDG3 receptor-mediated PLD activation.


View larger version (19K):
[in this window]
[in a new window]
  		Fig. 1.   Dose and time dependence of S1P-induced PLD activation in EDG3-overexpressing CHO-K1 cells. [3H]Palmitate-labeled cells were stimulated with the indicated concentrations of S1P for 5 min (A) and with 1 µM S1P for the indicated time periods (B). PBut formation was measured as described under "Experimental Procedures." The results are expressed as the mean ± S.E. from three different experiments in each duplicate.

Involvement of PLD in S1P-induced PI3K Activation-- S1P induced stimulation of the PI3K activity in time- and dose-dependent manners with a peak response at 5 min and a maximal concentration of 1 µM S1P, respectively (Fig. 2, A and B). To assess the involvement of PLD in S1P-induced PI3K activation, we examined the effects of treatments with 1-butanol and 2-butanol on S1P-induced PI3K activation. In the presence of 1-butanol but not 2-butanol, PBut was efficiently produced at the expense of PA by the transphosphatidylation activity of PLD (Fig. 3A, top panel). This effect of 1-butanol was maximal at a concentration of 0.3% (v/v) (Fig. 3A, bottom panel). The presence of 1-butanol at 0.3% almost totally suppressed S1P-induced activation of PI3K (Fig. 3B). In contrast, 2-butanol was without any effect on S1P-induced PI3K activation. These results indicate that the product of PLD, PA, is involved in S1P-induced PI3K activation.


View larger version (26K):
[in this window]
[in a new window]
  		Fig. 2.   Time and dose dependence of S1P-induced PI3K activation. EDG3-CHO-K1 cells were stimulated with 1 µM S1P for the indicated time periods (A) and with the indicated concentrations of S1P for 5 min (B). The cell lysates were subjected to immunoprecipitation with PY-20 antibody. The immunocomplex was assayed for PI3K activity as described under "Experimental Procedures." The results shown are representative of at least three independent experiments. The data are the mean ± S.E. of three different experiments in each duplicate.


View larger version (34K):
[in this window]
[in a new window]
  		Fig. 3.   Effects of 1-butanol and 2-butanol on PBut production and PI3K activation in S1P-stimulated EDG3-CHO-K1 cells. A, before stimulation with 1 µM S1P for 5 min, [3H]palmitate-labeled cells were incubated with different concentrations of 1-butanol or 2-butanol for 10 min. Production of PBut and PA was measured as described under "Experimental Procedures." Results are expressed as the mean ± S.E. of three different experiments. B, before stimulation with 1 µM S1P for 5 min, EDG3-CHO-K1 cells were incubated with 1-butanol (0.3%) or 2-butanol (0.3%) for 10 min. The cell lysates were then subjected to immunoprecipitation with PY-20 antibody. The immunocomplexes were assayed for PI3K activity as described under "Experimental Procedures." The data are the mean ± SD of three different experiments in each duplicate.

Dependence of S1P-induced Akt Activation on PI3K and PLD-- As shown in Fig. 4, S1P induced marked phosphorylation of Akt at Ser-473 in a time-dependent manner (Fig. 4A). The stimulatory effect of S1P on Akt phosphorylation was also dose-dependent, with a maximum response observed at 1 µM (Fig., 4B). Pretreatment with the PI3K inhibitors wortmannin (100 nM) and LY294002 (10 µM) suppressed S1P-induced Akt activation by >80% (Fig. 4C), indicating that activation of Akt is mediated by PI3K. In contrast, PI3K inhibitors had no effect at all on S1P-induced PLD activation (Fig. 4D).


View larger version (47K):
[in this window]
[in a new window]
  		Fig. 4.   Time and dose dependence of S1P-induced phosphorylation of Akt and the effects of PI3K inhibitors on Akt phosphorylation and PLD activation. EDG3-CHO-K1 cells were stimulated with 1 µM S1P for the indicated time periods (A) and with the indicated concentrations of S1P for 5 min (B). C, before stimulation with 1 µM S1P for 5 min, EDG3-CHO-K1 cells were treated with or without wortmannin (WTM) (100 nM) or LY294002 (10 µM) for 30 min. Cell lysates were subjected to 10% SDS-polyacrylamide gel electrophoresis, and proteins were blotted with anti-phospho-Akt (Ser-473) or anti-Akt antibodies. The results are representative of three different experiments. The phosphorylated protein bands were subjected to densitometric analysis, and the results are expressed as the mean ± S.E. of three different experiments. D, before stimulation with 1 µM S1P for 5 min, [3H]palmitate-labeled EDG3-CHO-K1 cells were pretreated with or without wortmannin (WTM) (100 nM) or LY294002 (LY) (10 µM) for 30 min. PBut formation was measured as described under "Experimental Procedures." The results are expressed as the mean ± S.E. from three different experiments in each duplicate.

Treatment of cells with 1-butanol (0.3%) completely abolished S1P-induced phosphorylation of Akt (Fig. 5A), a finding that was consistent with inhibition by 1-butanol of S1P-induced PI3K activation (Fig. 3B). The inhibition by 1-butanol of S1P-induced Akt activation was dependent on the concentration of 1-butanol (Fig. 5B), with a concentration-response relationship similar to those for PBut formation and inhibition of PA accumulation (Fig. 3A). 2-Butanol was again ineffective in inhibiting S1P-induced Akt activation.


View larger version (23K):
[in this window]
[in a new window]
  		Fig. 5.   Effects of 1-butanol and 2-butanol on S1P-induced Akt activation in EDG3-CHO-K1 cells. A, effects of butanol on phosphorylation of Akt. Before stimulation with 1 µM S1P for 5 min, EDG3-CHO-K1 cells were incubated with 1-butanol (0.3%) or 2-butanol (0.3%) for 10 min. Cell lysates were subjected to 10% polyacrylamide gel electrophoresis and blotted with anti-phospho-Akt (Ser-473) or anti-Akt antibodies. The results are representative of three different experiments. B, dose-dependent inhibition of 1-butanol on Akt phosphorylation. Before stimulation with 1 µM S1P for 5 min, EDG3-CHO-K1 cells were incubated with different concentrations of 1-butanol or 2-butanol for 10 min. Cell lysates were subjected to 10% polyacrylamide gel electrophoresis and blotted with anti-phospho-Akt (Ser-473) antibody. The extent of phosphorylation was quantitated by densitometer and expressed as the mean ± S.E. of three different experiments.

The involvement of PLD in S1P-induced Akt activation was further examined by transiently expressing wild-types and catalytically inactive mutants of PLD1 and PLD2. These catalytically inactive mutants have been shown to be devoid of activity both in vivo and in vitro when using phosphatidylcholine as a substrate, to be distributed intracellularly in a manner similar to that of the respective wild-type proteins, and to inhibit the activation of endogenous PLD when overexpressed (17). In the transfected cells, expression levels of transduced PLD gene products were higher than those of endogenous PLD1 and PLD2, as assessed by Western blotting analysis with specific anti-PLD1 and anti-PLD2 antibodies (Fig. 6A). We co-transfected cells with an expression vector for myc-tagged Akt and an expression vector for either the wild-type or the inactive mutant of PLD1 and PLD2 or the empty vector. We then immunoprecipitated myc-tagged Akt and performed an immunocomplex kinase assay using Crosstide as a substrate peptide. As shown in Fig. 6B, the expression levels of myc-Akt protein in transfected cells were nearly identical among the samples, as assessed by Western blotting analysis with anti-Akt antibody. In vector-transfected cells, S1P stimulated Akt activity by approximately 2-fold (Fig. 6C). Expression of wild-type PLD1 slightly increased basal and S1P-stimulated PLD1 activities. The effect of wild-type PLD2 expression was more prominent, resulting in an approximately 2-fold increase in S1P-stimulated Akt activity. Furthermore, expression of a catalytically inactive mutant of PLD2 almost completely abolished S1P-induced Akt activation. Expression of a catalytically inactive mutant of PLD1 slightly inhibited basal and S1P-stimulated Akt activities. All of these results demonstrate that in EDG3-CHO-K1 cells, PA produced via the action of PLD2 rather than that of PLD1 participates in S1P-induced activation of Akt.


View larger version (33K):
[in this window]
[in a new window]
  		Fig. 6.   Effects of expression of wild-type and catalytically inactive PLD on S1P-induced Akt activation. A, EDG3-CHO-K1 cells were transiently transfected with PLDs (lane 1, vector; lane 2, wild-type PLD1(WT); lane 3, catalytically inactive PLD1(K/R); lane 4, wild-type PLD2(WT) ; lane 5, catalytically inactive PLD2(K/R)), and cell proteins were examined by Western blotting with anti-PLD antibody recognizing both PLD1 and PLD2. B, EDG3-CHO-K1 cells were transiently co-transfected with myc-Akt and PLDs, vector, wild-type PLD1(WT) or PLD2(WT), or catalytically inactive PLD1(K/R) or PLD2 (K/R). After 24 h, these cells were stimulated with or without S1P (1 µM for 10 min), and cell lysates were immunoprecipitated with anti-myc antibody. The immunoprecipitates were subjected to Western blot analysis with anti-Akt antibody. C, Akt activity in the immunoprecipitates was examined by determining the phosphorylation of Crosstide as a substrate as described under "Experimental Procedures." The result shown is representative of at least three independent experiments. The data are the mean ± S.D. of three different experiments in each duplicate.

Inhibitory Effects of 1-Butanol on S1P-induced Membrane Ruffling-- S1P induced membrane ruffling in EDG3-CHO-K1 cells (Fig. 7, a and b). This action of S1P was inhibited by wortmannin and LY294002 (data not shown), indicating the dependence of S1P-induced membrane ruffling on PI3K. 1-Butanol (0.3%) abolished S1P-induced membrane ruffling (Fig. 7c), whereas 2-butanol was without effect (Fig. 7d). These observations are consistent with the finding that PLD mediates S1P-induced PI3K activation (Fig. 3B).


View larger version (143K):
[in this window]
[in a new window]
  		Fig. 7.   Inhibitory effects of 1-butanol on S1P-induced membrane ruffling. EDG3 cells were not stimulated (a) or stimulated (b-d) with 0.1 µM S1P for 30 min in the absence (a and b) or presence of 1-butanol (0.3%) (c) or 2-butanol (0.3%) (d) and then fixed and stained for F-actin with Alexa Fluor 546 phalloidin. The results shown are representative of three experiments with similar results.

Activation of PI3K and Akt by Exogenous S. chromofuscus PLD-- To gain further insight into the link between PLD and the PI3K/Akt signaling pathway, we examined the effects of PA generation induced by exogenous S. chromofuscus PLD (PLDSc) on the activities of PI3K and Akt. Treatment of cells with PLDSc caused increases in PA production in a time- and dose-dependent manner (Fig. 8A). The maximal PA generation by 10 units/ml PLDSc was ~80% of that by 1 µM S1P (Fig. 8B). As shown in Fig. 9, treatment with PLDSc induced stimulation of PI3K activity in a dose-dependent manner, with activity reaching a maximum at 10 units/ml. The maximal increase in PI3K activity induced by PLDSc was ~80% of that by 1 µM S1P; this relative potency of PLDSc was similar to that of PLDSc in PA generation. Treatment of cells with PLDSc also stimulated phosphorylation of Akt in a time- and dose-dependent manner (Fig. 10). The time course and dose-response relationship for Akt stimulation by PLDSc were similar to those of PA formation (compare Figs. 8 and 10). The PLDSc -induced Akt phosphorylation was abolished by pretreatment with LY294002, indicating that PLDSc-induced Akt activation is mediated by PI3K.


View larger version (26K):
[in this window]
[in a new window]
  		Fig. 8.   Time and dose dependence of PA production caused by exogenous S. chromofuscus PLD in EDG3-CHO-K1 cells. A, [3H]Palmitate-labeled EDG3-CHO-K1 cells were treated with the indicated concentrations of PLDSc for 5 min and with 10 units/ml PLDSc for the indicated time intervals. B, the radiolabeled cells were treated with PLDSc (10 units/ml, 5 min) and stimulated with 1 mM S1P for 5 min. [3H]PA generation was measured as described under "Experimental Procedures." The data are the mean ± S.E. of two different experiments in each duplicate.


View larger version (37K):
[in this window]
[in a new window]
  		Fig. 9.   Stimulation of PI3K activity induced by exogenous S. chromofuscus PLD in EDG3-CHO-K1 cells. EDG3-CHO-K1 cells were incubated with various concentrations of PLDSc for 10 min, and cell lysates were subjected to immunoprecipitation with anti-phosphotyrosine antibody (PY-20). PI3K activity in the immunoprecipitates was measured with or without LY294002 as described under "Experimental Procedures." The results shown are representative of three independent experiments. The data are the mean ± S.E. of three different experiments.


View larger version (33K):
[in this window]
[in a new window]
  		Fig. 10.   Stimulation of Akt phosphorylation induced by exogenous S. chromofuscus PLD in EDG3-CHO-K1 cells. EDG3-CHO-K1 cells were treated with various concentrations of PLDSc for 10 min (A) and with 10 units/ml PLDSc for the indicated time intervals with or without preincubation with LY294002 (B). Cell lysates were subjected to 10% polyacrylamide gel electrophoresis and blotted with anti-phospho-Akt (Ser-473) or anti-Akt antibodies. The results shown are representative of three independent experiments.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

PLD is activated rapidly in response to diverse extracellular stimuli, including hormones, growth factors, neurotransmitters, cytokines, antigens, and certain physical stresses (1-5). The initial product of PLD, PA, is thought to serve a signaling function. However, the intracellular targets for this lipid messenger have not been clearly identified. In this study, we demonstrated that PLD stimulation is necessary for S1P-induced activation of PI3K and its downstream effector Akt, and is sufficient for inducing activation of both PI3K and Akt under certain conditions. This is the first report to indicate the involvement of PLD and PA in in vivo activation of PI3K and its effector Akt. This conclusion is based on the following three major findings: (a) S1P-induced activation of PI3K and Akt was inhibited by 1-butanol, which served as a phosphatidyl group acceptor in the PLD-catalyzed transphosphatidylation reaction to reduce the levels of PA. In contrast, 2-butanol, which did not serve as a phosphatidyl group acceptor, was ineffective; (b) S1P-induced activation of Akt was suppressed by the overexpression of a dominant negative PLD2 mutant; and (c) treatment of cells with exogenous PLDSc induced activation of PI3K and Akt, and Akt activation was completely abolished by a PI3K inhibitor, LY294002. Moreover, S1P-induced membrane ruffling, which was dependent upon PI3K (39), was abolished by 1-butanol, but not by 2-butanol. These observations point to an essential role for PLD and PA in PI3K activation induced by the G protein-coupled receptor agonist S1P.

Many studies have indicated that S1P induces cell proliferation, suppression of apoptosis, modulation of cell motility, and cell shape changes (18-24, 39, 46). The EDG receptors for S1P, including EDG3, have been shown to mediate S1P-evoked signaling events relevant to cell proliferation and survival, including the activation of extracellular signal-regulated kinase (33). We have previously demonstrated that S1P-induced PLD activation is independent of extracellular signal-regulated kinase activation in NIH3T3 cells (25). In the present study, we have demonstrated that S1P-induced activation of PLD is required for activation of PI3K and Akt in EDG3-expressing CHO-K1 cells. It is widely accepted that the activation of Akt plays a pivotal role in cell survival and protection against apoptosis by phosphorylating BAD and caspase-9 and by regulating signaling via transcription factors such as the forkhead family and nuclear factor kappa B (41, 47, 48). On the other hand, it has previously been shown that PLDs are also involved in cell survival signaling events; for example, overexpression of PLD2 suppresses H2O2- and hypoxia-induced apoptosis in PC12 cells (34, 36). Our results reveal a novel link between PLD and the PI3K/Akt pathway in S1P-mediated survival signaling.

There is some existing evidence indicating a functional link between PLD and PI3K. For example, PLD and PI3K are regulated by receptor tyrosine kinases. Similar to PI3K, PLD is regulated by RalA, a downstream target of Ras, in platelet-derived growth factor- and epidermal growth factor-stimulated cells (49, 50), and PLD2 is tyrosine-phosphorylated by forming a physical complex with the epidermal growth factor receptor (51). Recent studies have demonstrated that PLD1 and PI3K play a role in GLUT4 translocation between the plasma membranes and intracellular vesicles in insulin-stimulated cells (52). Furthermore, several studies have demonstrated through the use of PI3K inhibitors that PI3K is involved in agonist-stimulated PLD activation (53-56). These studies suggest, as a possible underlying mechanism, that the PI3K products phosphatidylinositol 3,4-bisphosphate, and phosphatidylinositol 3,4,5-trisphosphate might regulate the activity of the Ras-related low molecular mass GTPases Rho and Arf, which have been shown to be involved in the activation of PLD (1-5). We have observed that Clostridium difficile toxin B, which inactivates all Rho G proteins including Rho, Rac, and Cdc42 (57), blocks all S1P-induced activation of PLD, PI3K, and Akt in EDG3- CHO-K1 cells (data not shown). Our previous study, however, demonstrated that S1P-induced Rac activation occurs downstream from PI3K activation in EDG3-CHO-K1 cells (39). In the present study, PI3K inhibitors had no effect on S1P-induced PLD activation in EDG3-CHO-K1 cells (Fig. 4D), whereas 1-butanol inhibited S1P-induced PI3K activation (Fig. 3B). These observations indicate that PI3K exists downstream rather than upstream of PLD in EDG3-CHO-K1 cells.

Among the PI3Ks, two isoforms of PI3K catalytic subunits, p110alpha and p110beta , form heterodimers with the p85/p55 adaptor subunits, whereas another catalytic subunit, p110gamma , is associated with the p101 adaptor. p85/p55-associated p110alpha and p110beta are stimulated by tyrosine kinase-coupled transmembrane receptors upon their recruitment to the plasma membrane by the assembly of phosphotyrosine-containing multimolecular complexes. Ras is also thought to participate in the activation of p110alpha and p110beta through its direct binding to these catalytic subunits. On the other hand, p110gamma and p110beta have been shown to be stimulated by the heterotrimeric G proteins (58, 59). Previous studies have shown that PA and lyso-PA inhibit PI3K activity in in vitro systems, whereas these lipids activate phosphatidylinositol 4-kinase, phospholipase C, protein kinase C, and Lck tyrosine kinase under the same conditions (60, 61). On the other hand, a recent study has demonstrated that anionic phospholipids such as phosphatidylinositol 4,5-bisphosphate, PA, and phosphatidylserine can bind to p110 (62). Therefore, it is an interesting possibility that PA produced by PLD activation participates in the recruitment of PI3K to the plasma membrane in S1P-stimulated cells. In the present study, we observed stimulation of PI3K activity in anti-phosphotyrosine antibody immunoprecipitates from S1P-stimulated EDG3-CHO-K1 cells (Fig. 3), indicating that S1P-stimulated PI3K activity is associated with a phosphotyrosine-containing protein or that PI3K is directly tyrosine-phosphorylated. A number of studies have demonstrated that exogenously added and endogenously generated PA induces enhancement of tyrosine phosphorylation in neutrophils and other cell types (63-65). A more recent study has demonstrated that exogenous PA induces tyrosine phosphorylation of the p85 regulatory subunit of PI3K in neutrophilic leukocytes (66). Therefore, it is tempting to speculate that PA-dependent tyrosine phosphorylation may be involved in recruitment to the plasma membrane and stimulation of the PI3K in the EDG3-mediated response to S1P. However, additional experiments are required to prove this hypothesis.

    ACKNOWLEDGEMENT

We thank Dr. Michael A. Frohmann for providing the plasmid encoding wild-type and catalytically inactive mutants of PLD1 and PLD2.

    FOOTNOTES

* This work was supported in part by Grants-in-aid for Scientific Research on Priority Areas 09273104 and 10212204 and Grants-in-aid for Scientific Research (C) 12680633 from the Ministry of Education, Science, Sports, and Culture of Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Dept. of Biochemistry, Gifu University School of Medicine, Tsukasamachi-40, Gifu, 500-8705, Japan. Tel.: 81-58-267-2229; Fax: 81-58-265-9002; E-mail; banno@cc.gifu-u.ac.jp.

Published, JBC Papers in Press, July 23, 2001, DOI 10.1074/jbc.M105673200

    ABBREVIATIONS

The abbreviations used are: PA, phosphatidic acid; PBut, phosphatidylbutanol; PI3K, phosphatidylinositol 3-kinase; PLD, phospholipase D; PLDSc, Streptomyces chromofuscas PLD; S1P, sphingosine 1-phosphate; CHO, Chinese hamster ovary; PI3P, PI3-phosphate.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Exton, J. H. (1999) Biochim. Biophys. Acta 1439, 121-133
2. Jones, D., Morgan, C., and Cockcroft, S. (1999) Biochim. Biophys. Acta 1439, 229-244
3. Liscovitch, M., Czarny, M., Fiucci, G., and Tang, X. (2000) Biochem. J. 345, 401-415
4. Frohman, M. A., Sung, T. C., and Morris, A. J. (1999) Biochim. Biophys. Acta 1439, 175-186
5. Meier, K. E., Gibbs, T. C., Knoepp, S. M., and Ella, K. M. (1999) Biochim. Biophys. Acta 1439, 199-213
6. Ghosh, S., Strum, J. C., Sciorra, V. A., Daniel, L. W., and Bell, R. M. (1996) J. Biol. Chem. 271, 8472-8480
7. Limatola, C., Barabino, B., Nista, A., and Santoni, A. (1997) Biochem. J. 321, 497-501
8. Waite, K. A., Wallin, R., Qualliotine-Mann, D., and McPhail, L. C. (1997) J. Biol. Chem. 272, 15569-15578
9. Bokoch, G. M., Reilly, A. M., Daniels, R. H., King, C. C., Olivera, A., Spiegel, S., and Knaus, U. G. (1998) J. Biol. Chem. 273, 8137-8144
10. Kishikawa, K., Chalfant, C. E., Perry, D. K., Bielawska, A., and Hannun, Y. A. (1999) J. Biol. Chem. 274, 21335-21341
11. Tsai, M.-H., Yu, C.-L., Wei, F.-S., and Stacey, D. W. (1989) Science 243, 522-526
12. Melendez, A., Andres, F., Gillooly, D. J., Harnett, M. M., and Allen, J. M. (1998) J. Biol. Chem. 273, 9393-9402
13. Moritz, A., De Graan, P. N. E., Gispen, W. H., and Wirtz, K. W. A. (1992) J. Biol. Chem. 267, 7207-7210
14. Jones, G. A., and Carpenter, G. (1993) J. Biol. Chem. 268, 20845-20850
15. Litosch, I. (2000) Biochemistry 39, 7736-7743
16. Palicz, A., Foubert, T. R., Jesaitis, A. J., Marodi, L., and McPhail, L. C. (2001) J. Biol. Chem. 276, 3090-3097
17. Rizzo, M. A., Shome, K., Vasudevan, C., Stolz, D. B., Sung, T. C., Frohman, M. A., Watkins, S. C., and Romero, G. (1999) J. Biol. Chem. 274, 1131-1139
18. An, S. (2000) Ann. N. Y. Acad. Sci. 905, 25-33
19. Pyne, S., and Pyne, N. J. (2000) Biochem. J. 349, 385-402
20. Spiegel, S., and Milstien, S. (2000) Biochim. Biophys. Acta 1484, 107-116
21. Chun, J., Contos, J. J., and Munroe, D. (1999) Cell Biochem. Biophys. 30, 213-242
22. Hla, T., Lee, M. J., Ancellin, N., Liu, C. H., Thangada, S., Thompson, B. D., and Kluk, M. (1999) Biochem. Pharmacol. 58, 201-217
23. Igarashi, Y. (1998) Ann. N. Y. Acad. Sci. 845, 19-31
24. Moolenaar, W. H. (1999) Exp. Cell Res. 253, 230-238
25. Banno, Y., Fujita, H., Ono, Y., Nakashima, S., Ito, Y., Kuzumaki, N., and Nozawa, Y. (1999) J. Biol. Chem. 274, 27385-27391
26. Koh, J., Satao, K., Watanabe, T., Tomura, H., Kuwabara, A., Kimura, T., Tamama, K., Ishizuka, T., Murata, N., Kanda, T., Kobayashi, I., Ohta, H., Ui, M., and Okajima, F. (1999) J. Biol. Chem. 274, 23940-23947
27. Ohmori, T., Yatomi, Y., Okamoto, H., Miura, Y., Rile, G., Satoh, K., and Ozaki, Y. (2001) J. Biol. Chem. 276, 5274-5280
28. Okamoto, H., Takuwa, N., Gonda, K., Okazaki, H., Chang, K., Yatomi, Y., Shigematsu, H., and Takuwa, Y. (1998) J. Biol. Chem. 273, 27104-27110
29. Okamoto, H., Takuwa, N., Yatomi, Y., Gonda, K., Shigematsu, H., and Takuwa, Y. (1999) Biochem. Biophys. Res. Commun. 260, 203-208
30. Orlati, S., Porceli, A. M., Hrelia, S., Van Brocklyn, J. R., Spiegel, S., and Rugolo, M. (2000) Arch. Biochem. Biophys. 375, 69-77
31. Rakhit, S., Conway, A. M., Tate, R., Bower, T., Pyne, N. J., and Pyne, S. (1999) Biochem. J. 338, 643-649
32. Goetzl, E. J., Kong, Y., and Mei, B. (1999) J. Immunol. 162, 2049-2056
33. An, S., Zheng, Y., and Bleu, T. (2000) J. Biol. Chem. 275, 288-296
34. Lee, S. D., Lee, B. D., Han, J. M., Kim, J. H., Kim, Y., Suh, P. G., and Ryu, S. H. (2000) J. Neurochem. 75, 1053-1059
35. Nakashima, S., and Nozawa, Y. (1999) Chem. Phys. Lipids 98, 153-164
36. Yamakawa, H., Banno, Y., Nakashima, S., Sawada, M., Yamada, J., Yoshimura, S., Nishimura, Y., Nozawa, Y., and Sakai, N. (2000) Neuroreport 11, 3647-3650
37. Zhang, Y., Redina, O., Altshuller, Y. M., Yamazaki, M., Ramos, J., Chneiweiss, H., Kanaho, Y., and Frohman, M. A. (2000) J. Biol. Chem. 275, 35224-35232
38. Marte, B., M., and Downward, J. (1997) Trends Biochem. Sci. 22, 355-358
39. Okamoto, H., Takuwa, N., Yokomizo, T., Sugimoto, N., Sakurada, S., Shigematsu, H., and Takuwa, Y. (2000) Mol. Cell. Biol. 20, 9247-9261
40. Honda, A., Nogami, M., Yokozeki, T., Yamazaki, M., Nakamura, H., Watanabe, H., Kawamoto, K., Nakayama, K, Morris, A. J., Frohman, M. A., and Kanaho, Y. (1999) Cell 99, 521-532
41. Data, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. (1997) Cell 91, 231-241
42. Chang, K., Hanaoka, K., Kumada, M., and Takuwa, Y. (1995) J. Biol. Chem. 270, 26152-26158
43. Steele-Mortimer, O., Knodler, L. A., Marcus, S. L., Scheid, M. P., Goh, B., Pfeifer, C. G., Duronio, V., and Finlay, B. B. (2000) J. Biol. Chem. 275, 37718-37724
44. Ruderman, N. B., Kapeller, R., White, M. F., and Cantley, L. C. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 1411-1415
45. Yano, H., Nakanishi, S., Kimura, K., Hanai, N., Saitoh, Y., Fukui, Y., Nonomura, Y., and Matsuda, Y. (1993) J. Biol. Chem. 268, 25846-25856
46. Takuwa, Y., Okamoto, H., Takuwa, N., Gonda, K., Sugimoto, N., and Sakurada, S. (2001) Mol. Cell. Endocrinol. 177, 3-11
47. Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. R., Franke, T. F., Stanbridge, E., Frisch, S., and Reed, J. C. (1998) Science 282, 1318-1321
48. Kane, L. P., Shapiro, V. S., Stokoe, D., and Weiss, A. (1999) Curr. Biol. 9, 601-604
49. Lucas, L., del Peso, L., Rodriguez, P., Penalva, V., and Lacal, J. C. (2000) Oncogene 19, 431-437
50. Slaaby, R., Jensen, T., Harald, H. S., Frohman, M. A., and Seedorf, K. (1998) J. Biol. Chem. 273, 33722-33727
51. Lu, Z., Horna, A., Joseph, T., Sukezane, T., Frankel, P., Zhong, M., Bychenok, S., Xu, L., Feig, L. A., and Foster, D. A. (2000) Mol. Cell. Biol. 20, 462-467
52. Emoto, M., Klarlind, J. K., Waters, S. B., Hu, V., Buxton, J. M., Chawla, A., and Czech, M. P. (2000) J. Biol. Chem. 275, 7144-7151
53. Cissel, D. S., Fraundorfer, P. F., and Beaven, M. A. (1998) J. Pharmacol. Exp. Ther. 285, 110-118
54. Gillooly, D. J., Melendez, A. J., Hockaday, A. R., Harnett, M. M., and Allen, J. M. (1999) Biochem. J. 344, 605-611
55. Kozawa, O., Blume-Jensen, P., Heldin, C. H., and Ronnstrand, L. (1997) Eur. J. Biochem. 248, 149-155
56. Nakamura, M., Nakashima, S., Katagiri, Y., and Nozawa, Y. (1997) Biochem. Pharmacol. 53, 1929-1936
57. Just, L., Selzer, J., Wilm, M., Von Eichel-Streiber, C., Mann, M., and Aktries, K. (1995) Nature 375, 500-504
58. Rameh, L. E., and Cantley, L. C. (1999) J. Biol. Chem. 274, 8347-8350
59. Stephens, L., Eguinoa, A., Corey, S., Jackson, T., and Hawkins, P. T. (1993) EMBO J. 12, 2265-2273
60. Lauener, R., Shen, Y., Duronio, V., and Salari, H. (1995) Biochem. Biophys. Res. Commun. 215, 8-14
61. Lavie, Y., and Agranoff, B. W. (1996) J. Neurochem. 66, 811-816
62. Kirsch, C., Wetzker, R., and Klinger, R. (2001) Biochem. Biophys. Res. Commun. 282, 691-696
63. Ohguchi, K., Kasai, T., and Nozawa, Y. (1997) Biochim. Biophys. Acta 1346, 301-304
64. Sergeant, S., Waite, K. A., Heravi, J., and McPhail, L. C. (2001) J. Biol. Chem. 276, 4737-4746
65. Siddiqui, R. A., and English, D. (1997) Biochim. Biophys. Acta 1349, 81-95
66. Siddiqui, R. A., and English, D. (2000) Biochim. Biophys. Acta 1483, 161-173

Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
C. A. Farah, I. Nagakura, D. Weatherill, X. Fan, and W. S. Sossin
Physiological Role for Phosphatidic Acid in the Translocation of the Novel Protein Kinase C Apl II in Aplysia Neurons
Mol. Cell. Biol., August 1, 2008; 28(15): 4719 - 4733.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. Gorshkova, D. He, E. Berdyshev, P. Usatuyk, M. Burns, S. Kalari, Y. Zhao, S. Pendyala, J. G. N. Garcia, N. J. Pyne, et al.
Protein Kinase C-{epsilon} Regulates Sphingosine 1-Phosphate-mediated Migration of Human Lung Endothelial Cells through Activation of Phospholipase D2, Protein Kinase C-{zeta}, and Rac1
J. Biol. Chem., April 25, 2008; 283(17): 11794 - 11806.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
N. Lehman, B. Ledford, M. Di Fulvio, K. Frondorf, L. C. McPhail, and J. Gomez-Cambronero
Phospholipase D2-derived phosphatidic acid binds to and activates ribosomal p70 S6 kinase independently of mTOR
FASEB J, April 1, 2007; 21(4): 1075 - 1087.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. J. French, J. J. Upson, S. N. Keller, Y. Zhuang, J. K. Yun, and C. D. Smith
Antitumor Activity of Sphingosine Kinase Inhibitors
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 596 - 603.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. Dunnick, P. Blackshear, G. Kissling, M. Cunningham, J. Parker, and A. Nyska
Critical Pathways in Heart Function: Bis(2-chloroethoxy)methane-Induced Heart Gene Transcript Change in F344 Rats
Toxicol Pathol, June 1, 2006; 34(4): 348 - 356.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
L. Brizuela, M. Rabano, A. Pena, P. Gangoiti, J. M. Macarulla, M. Trueba, and A. Gomez-Munoz
Sphingosine 1-phosphate: a novel stimulator of aldosterone secretion
J. Lipid Res., June 1, 2006; 47(6): 1238 - 1249.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Ammoun, D. Lindholm, H. Wootz, K. E. O. Akerman, and J. P. Kukkonen
G-protein-coupled OX1 Orexin/hcrtr-1 Hypocretin Receptors Induce Caspase-dependent and -independent Cell Death through p38 Mitogen-/Stress-activated Protein Kinase
J. Biol. Chem., January 13, 2006; 281(2): 834 - 842.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Nozawa, T. Ohno, Y. Banno, T. Dohjima, K. Wakahara, D.-G. Fan, and K. Shimizu
Inhibition of Platelet-derived Growth Factor-induced Cell Growth Signaling by a Short Interfering RNA for EWS-Fli1 via Down-regulation of Phospholipase D2 in Ewing Sarcoma Cells
J. Biol. Chem., July 29, 2005; 280(30): 27544 - 27551.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Osawa, H. Uchinami, J. Bielawski, R. F. Schwabe, Y. A. Hannun, and D. A. Brenner
Roles for C16-ceramide and Sphingosine 1-Phosphate in Regulating Hepatocyte Apoptosis in Response to Tumor Necrosis Factor-{alpha}
J. Biol. Chem., July 29, 2005; 280(30): 27879 - 27887.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page